Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Genmab A/S

Genmab ( ($GMAB) ) has provided an announcement. On January 29, 2026, Genmab A/S announced that its board had granted 32,806 restricted stock units...

Genmab Grants New RSUs and Warrants to Employees to Strengthen Long-Term Incentives

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) and Gen...

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Genmab (GMAB)

Genmab ( ($GMAB) ) has shared an update. On January 21, 2026, Genmab reported that 2025 worldwide net trade sales of the multiple myeloma therapy D...

Genmab Reports 2025 DARZALEX Net Sales of USD 14.4 Billion

In a report released on January 19, Jon Berggren from Kepler Capital maintained a Hold rating on Genmab A/S, with a price target of DKK2,100.00. Th...

Kepler Capital  Sticks to Its Hold Rating for Genmab A/S (0MGB)

UBS analyst Xian Deng maintained a Buy rating on Genmab A/S today and set a price target of DKK2,750.00. Deng covers the Healthcare sector, focusin...

Genmab A/S (0MGB) Gets a Buy from UBS

In a report released today, James Gordon CFA from Barclays maintained a Buy rating on Genmab A/S, with a price target of DKK2,500.00. The word on T...

Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)

Genmab ( ($GMAB) ) has shared an announcement. On January 16, 2026, Genmab reported topline Phase 3 results from its global EPCORE DLBCL-1 trial of...

Genmab Reports Positive Phase 3 Progression-Free Survival Data for Epcoritamab in Relapsed/Refractory DLBCL

In a report released today, Xian Deng from UBS maintained a Buy rating on Genmab A/S, with a price target of DKK2,750.00. According to TipRanks, De...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMAB	$33.27	+1.96%	880.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMAB	$33.27	+2.0%	880.30K
3
4
5
6

GMAB

GMAB

Get Genmab A/S Data in Excel

Get Genmab A/S Data in Excel